Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide PK and Switch to Deutenzalutamide in Chinese mCRPC Patients
NCT03778047Phase 1Completed
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Feb 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deutenzalutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Hinova Pharmaceuticals Inc. Primary endpoints: Maximum drug concentration (Cmax) of Enzalutamide, Time of maximum drug concentration (Tmax) of Enzalutamide and 1 more. Started Feb 2018; status: completed.
02
Drugs
deutenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03778047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778047.